Kripthonite Therapeutics ApS
APSActiveCVR 43770209Palle Juul-Jensens Boulevard 82, 8200 Aarhus NManufacture of pharmaceutical preparations· NACE 2120Est. 2023 · 3 years old4 employees
Loading company…
Overview
Kripthonite Therapeutics ApS is a Danish APS based in Aarhus N, operating in the Manufacture of pharmaceutical preparations sector. Incorporated in 2023, the company has 4 employees and reported a gross profit of -DKK 3.5m in its latest annual filing.
Gross profit 2025
-3.5M DKK
−2900% vs 2024
EBITDA margin (of gross profit)
140.7 %
Net profit 2025
-3.9M DKK
-12300756% vs 2024
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
95.9 %
Very strongAmong the 10% highest rated companies in the industry
20232025
Liquidity ratioCurrent assets ÷ Short-term debt
24.5×
Very strongAmong the 10% highest rated companies in the industry
20232025
Return on assets (ROA)Net profit ÷ Total assets × 100
-82.1 %
Very weakAmong the 10% lowest rated companies in the industry
20232025
EBITDA — year on year
DKK thousandsKey figures
Annual report 2025| Gross profit | -3.5M DKK | -2900% |
| EBITDA | -4.9M DKK | — |
| Net profit | -3.9M DKK | -12300756% |
| Total assets | 4.8M DKK | +2745% |
| Equity | 4.6M DKK | +13205% |
| Employees | 4 | — |
Company information
Legal name
Kripthonite Therapeutics ApS
CVR number
43770209
Legal form
Anpartsselskab
NACE code
Founded
10 January 2023 · 3 years
Share capital
DKK 47,813
Employees
4 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af to bestyrelsesmedlemmer i forening.
Company purpose
Selskabets formål er forskning og udvikling af lægemidler og dermed beslægtet virksomhed.
(no translation available)
Address
Palle Juul-Jensens Boulevard 82, 8200 Aarhus N
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2025), Kripthonite Therapeutics ApS reported a gross profit of -DKK 3.5m, a decrease of 2900% on the year before. The figures on this page draw on 3 annual filings covering 2023 to 2025. The bottom line showed a net loss of DKK 3.9m.
At the end of 2025, equity financed 95.9% of the balance sheet, and current assets covered short-term debt 24.5 times.
Financials
Gross profit
DKK thousandsEBITDA
DKK thousandsIncome statement
DKK thousands| Item | 2025 | 2024 | 2023 |
|---|---|---|---|
| Gross profit | -3,513 | 125 | 542 |
| Staff expenses | -1,431 | -125 | -546 |
| EBITDA | -4,944 | 0 | -5 |
| Depreciation & amort. | -0 | -0 | -0 |
| EBIT | -4,944 | 0 | -5 |
| Net financials | -24 | -0 | -1 |
| Profit before tax | -4,967 | -0 | -5 |
| Tax | -1,031 | -0 | -0 |
| Net profit | -3,936 | -0 | -5 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
DKK thousands| Item | 2025 | 2024 | 2023 |
|---|---|---|---|
| Total assets | 4,793 | 169 | 75 |
| Equity | 4,598 | 35 | 35 |
| Long-term debt | 0 | 0 | 0 |
| Short-term debt | 195 | 134 | 41 |
| Total debt | 195 | 134 | 41 |
Financial ratios
5-year trendEBITDA margin (of gross profit)
<−999 %
20232025
Equity ratio
95.9 %
Very strongAmong the 10% highest rated companies in the industry
20232025
Return on equity
-85.6 %
Very weakAmong the 10% lowest rated companies in the industry
20232025
Net profit margin (of gross profit)
<−999 %
20232025
Asset turnover (of gross profit)
-0.73×
20232025
Debt / equity
0.04×
Very strongAmong the 10% highest rated companies in the industry
20232025
Sector performance
23 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Return on equity (ROE)Very weak
Among the 10% lowest rated companies in the industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Very weak
Among the 10% lowest rated companies in the industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Very weak
Among the 10% lowest rated companies in the industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Very weak
Among the 10% lowest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Capacity ratioVery weak
Among the 10% lowest rated companies in the industry
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Gross marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Liquidity
Current ratioVery strong
Among the 10% highest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioVery strong
Among the 10% highest rated companies in the industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioVery strong
Among the 10% highest rated companies in the industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityStrong
Among the 30% highest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalVery strong
Among the 20% highest rated companies in the industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioAverage
Around the average of companies in the same industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioVery strong
Among the 10% highest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioVery strong
Among the 10% highest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityVery strong
Among the 10% highest rated companies in the industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityVery strong
Among the 10% highest rated companies in the industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtVery weak
Among the 10% lowest rated companies in the industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtVery weak
Among the 10% lowest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageVery weak
Among the 10% lowest rated companies in the industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtVery weak
Among the 10% lowest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginVery weak
Among the 10% lowest rated companies in the industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Efficiency & development
Equity to contributed capitalVery strong
Among the 10% highest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityVery strong
Among the 10% highest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtVery weak
Among the 20% lowest rated companies in the industry
The size of this year's increase or decrease in the company's debt.
Asset turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to total assets — the ability to generate revenue from the asset base.
Inventory turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Annual reports & filings
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JS Management | Management | 2026 |
Former (1)
EV Management | Management | 2023 – 2026 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
SB Chairman | Chairman | 2025 |
KM Board of Directors | Board of Directors | 2023 |
PH Board of Directors | Board of Directors | 2023 |
TB Board of Directors | Board of Directors | 2023 |
EV Board of Directors | Board of Directors | 2026 |
Former (1)
PH Chairman | Chairman | 2023 – 2025 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
| Company | 20–24.99% | 20–24.99% | 2025 | |
| Company | 20–24.99% | 20–24.99% | 2025 | |
| Company | 20–24.99% | 20–24.99% | 2025 | |
| Company | 20–24.99% | 20–24.99% | 2025 | |
| Company | 15–19.99% | 15–19.99% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
Marigold Innovation ApS
Kripthonite Therapeutics ApS (this company)Board network connections
Board members of Kripthonite Therapeutics ApS also hold positions in 16 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Peter Horn Møller | Chairman | 5 companies |
| Thomas Bjørnskov Poulsen | Board of Directors | 4 companies |
| Jan Stenvang | Management | 2 companies |
| Erik Vinther | Management | 2 companies |
| Søren Bregenholt Frederiksen | Chairman | 1 company |
| Kristian Mark Jacobsen | Board of Directors | 1 company |
| Per Hjerrild | Board of Directors | 1 company |
Frequently asked questions
What is the CVR number of Kripthonite Therapeutics ApS?
Kripthonite Therapeutics ApS is registered with CVR / Virk under CVR 43770209.
What is the gross profit of Kripthonite Therapeutics ApS?
Kripthonite Therapeutics ApS reported a gross profit of -DKK 3.5m in 2025.
How many employees does Kripthonite Therapeutics ApS have?
Kripthonite Therapeutics ApS employs 4 people as of the latest annual report.
Who is the chairman of Kripthonite Therapeutics ApS?
Søren Bregenholt Frederiksen chairs the board of Kripthonite Therapeutics ApS, in role since 2025.
Where is Kripthonite Therapeutics ApS headquartered?
Kripthonite Therapeutics ApS's registered address is Palle Juul-Jensens Boulevard 82.